Document ID: Y_1_06
Section: Altered States & Psychedelics
Keywords: psychedelic, entheogen, psilocybin, DMT, ayahuasca, LSD, mescaline, consciousness, mystical experience, neuroimaging, default mode network, serotonin 5-HT2A, Johns Hopkins, MAPS, therapeutic, PTSD, depression, ego dissolution, near-death experience, stoned ape, Terence McKenna, Rick Strassman
Category Tags: consciousness, nde-afterlife, psychedelics
Cross-References: Y_2_01 — Consciousness · Y_1_05 — Soma/Haoma · C_3_09 — Oracle Traditions · B_1_02 — Thoth · U_1_03 — Music & Acoustics
Reliability Tier: Tier 1-3 (modern clinical research is Tier 1; ancient entheogen identification is Tier 2–3; "stoned ape" hypothesis is Tier 3–4)
Last Updated: Mar 4, 2026 | Source Count: 15 | Weighted Score: 32 | Source Confidence: [4/5] | Confidence: High for clinical data; Medium for historical claims

QUICK SUMMARY

Psychedelic research has undergone a dramatic revival since ~2006, with major studies at Johns Hopkins, Imperial College London, NYU, and MAPS demonstrating the therapeutic potential of psilocybin, MDMA, and ayahuasca/DMT for treatment-resistant depression, PTSD, end-of-life anxiety, and addiction. Neuroimaging (fMRI, MEG) has revealed that psychedelics produce their consciousness-altering effects primarily through serotonin 5-HT2A receptor agonism and disruption of the Default Mode Network (DMN) — the brain network associated with the sense of self and habitual thought patterns. This document surveys the modern clinical evidence, the neurological mechanisms, and critically evaluates the connection between modern psychedelic experiences and ancient entheogen use documented in traditions from Vedic Soma to Eleusinian Mysteries to Mesoamerican mushroom cults. The ancient practices are real and well-attested; claims that psychedelics were the sole origin of religion or consciousness itself (Stoned Ape theory) remain speculative.

§1 — MODERN CLINICAL EVIDENCE

Key Clinical Trials

• FDA Breakthrough Therapy Designation: Psilocybin for treatment-resistant depression (Compass Pathways, 2018) and for major depressive disorder (Usona Institute, 2019). MDMA for PTSD (MAPS, 2017). Failed FDA advisory committee vote in 2024 due to trial design concerns, not efficacy doubts.
• Tier 1 — Published in New England Journal of Medicine, JAMA, Nature Medicine, Lancet

Neurological Mechanism

• 5-HT2A receptor agonism: All classical psychedelics (psilocybin/psilocin, LSD, DMT, mescaline) are serotonin 5-HT2A receptor agonists. The profound subjective effects are abolished by 5-HT2A antagonists (ketanserin), proving this receptor is the primary mechanism
• Default Mode Network (DMN) disruption: fMRI studies (Carhart-Harris et al., 2012) show psychedelics reduce activity and connectivity within the DMN — the brain network active during self-referential thought, mind-wandering, and autobiographical memory. This correlates with reported "ego dissolution"
• Increased global connectivity: Simultaneously, psychedelics increase connectivity between brain regions that do not normally communicate — producing a more "entropic" brain state (Carhart-Harris, "Entropic Brain Hypothesis," 2014)
• The connectome under psilocybin: Petri et al. (2014, Journal of the Royal Society Interface) showed that psilocybin creates novel network connections that disappear after the drug wears off — visualized as a "hyperconnected" network topology

§2 — ANCIENT ENTHEOGEN USE: DOCUMENTED EVIDENCE

Confirmed and Probable Ancient Psychedelic Use

§3 — DMT AND THE "SPIRIT MOLECULE" DEBATE

Rick Strassman's Studies

• Strassman (2001): Conducted DEA-approved clinical trial with intravenous DMT at University of New Mexico (1990–1995) — the first US psychedelic study in 20+ years
• Findings: Participants reported vivid encounters with "entities," "beings," geometric spaces, and experiences described as "more real than real." Many experiences resembled near-death and mystical experience reports
• The "spirit molecule" claim: Strassman hypothesized that endogenous DMT (produced in the human body) may be released during birth, death, and mystical experiences. This remains unproven:
• DMT has been detected in rat brain tissue (Barker et al., 2013, Biomedical Chromatography) — but at trace levels
• No study has demonstrated DMT release during death, birth, or NDEs in humans
• The pineal gland origin claim is unsupported — DMT synthesis enzymes are found in the lungs, liver, and other tissues, not specifically concentrated in the pineal
• Tier 2 — The clinical phenomenology is documented; the endogenous release theory is speculative (Tier 3)

§4 — COUNTER-ARGUMENTS AND CRITICAL ASSESSMENT

The "Stoned Ape" Hypothesis

• Terence McKenna (1992, Food of the Gods): Proposed that psilocybin mushroom consumption by Homo erectus on the African savanna catalyzed the evolution of human language, consciousness, and culture
• Problems:
• No archaeological evidence of Paleolithic psilocybin use
• The mechanism by which a temporary drug experience would produce heritable genetic change is not explained (this would require Lamarckian inheritance, which is discredited)
• Evolutionary psychology already provides mechanisms for language/consciousness evolution without psychedelics
• The timeline is vague — "some time in East Africa" — with no testable predictions
• Tier 3–4 — Interesting speculation; not a scientific theory (no testable predictions, no evidence)

Pharmacological Reductionism

• The claim: That all religious/mystical experience is "just" neurochemistry — psychedelics prove that visions of God are serotonin events
• Counter: This commits the genetic fallacy — knowing the mechanism of an experience does not determine its truth value or meaning. The fact that psilocybin has a known receptor mechanism does not prove or disprove the ontological status of what is experienced
• Scholarly position: Griffiths et al. note that participants' mystical experiences under psilocybin were indistinguishable from "naturally occurring" mystical experiences on validated measures (Hood's Mysticism Scale) — this cuts both ways

The "Soma Was Everything" Problem

• Multiple substances have been proposed as Soma/Haoma — fly agaric, ephedra, cannabis, Syrian rue, magic mushrooms. The lack of consensus after 50+ years of scholarship suggests the identification may be unresolvable with current evidence
• Generalizing from "some ancient rituals involved psychedelics" to "all ancient religion was entheogenic" is an overextension not supported by evidence

Counter-Arguments & Criticisms

Modern psychedelic research has generated both enthusiasm and methodological criticism. Muthukumaraswamy et al. (2021) argue that inadequate blinding—participants can easily identify whether they received a psychedelic or placebo—undermines many clinical trial results. The "mystical experience" hypothesis has been challenged by Olson (2021), whose research on non-hallucinogenic psychoplastogens suggests neuroplasticity rather than subjective experience may drive therapeutic effects. MAPS MDMA therapy trials have faced FDA scrutiny over methodology and adverse event reporting. Breeksema (2022) warns against "psychedelic exceptionalism" that overpromises therapeutic benefits. Historical parallels to the 1960s, when premature adoption contributed to regulatory prohibition, inform cautionary perspectives. The field acknowledges the need for larger, better-controlled trials before psychedelic therapies can be recommended as standard treatments.

IMAGES

Source Tier Classification

This document references sources across multiple evidence tiers within this project's reliability framework:

BIBLIOGRAPHY

1. Griffiths, Roland R., et al | 2006 | "Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance" | Psychopharmacology | ∅ | 187::268–283 | ∅ | ∅ | doi:10.1007/s00213-006-0457-5 | ∅ | ∅ | ∅
2. Griffiths, Roland R., et al | 2016 | "Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer" | Journal of Psychopharmacology | ∅ | 12::1181–1197 | 30, no | ∅ | doi:10.1177/0269881116675513 | ∅ | ∅ | ∅
3. Carhart-Harris, Robin L., et al | 2012 | "Neural Correlates of the Psychedelic State as Determined by fMRI Studies with Psilocybin" | PNAS | ∅ | 6::2138–2143 | 109, no | ∅ | doi:10.1073/pnas.1119598109 | ∅ | ∅ | ∅
4. Carhart-Harris, Robin L., et al | 2021 | "Trial of Psilocybin versus Escitalopram for Depression" | New England Journal of Medicine | ∅ | 384::1402–1411 | ∅ | ∅ | doi:10.1056/nejmoa2032994 | ∅ | ∅ | ∅
5. Mitchell, Jennifer M., et al | 2021 | "MDMA-Assisted Therapy for Severe PTSD" | Nature Medicine | ∅ | 27::1025–1033 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
6. Davis, Alan K., et al | 2021 | "Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder" | JAMA Psychiatry | ∅ | 5::481–489 | 78, no | ∅ | doi:10.1001/jamapsychiatry.2020.3285 | ∅ | ∅ | ∅
7. Strassman, Rick | 2001 | ∅ | DMT: The Spirit Molecule | ∅ | ∅ | Park Street Press | ∅ | isbn:9798587592179 | ∅ | ∅ | ∅
8. Barker, Steven A., et al | 2013 | "LC/MS/MS Analysis of the Endogenous Dimethyltryptamine Hallucinogens" | Biomedical Chromatography | ∅ | 12::1690–1700 | 27, no | ∅ | ∅ | ∅ | ∅ | ∅
9. Wasson, R | 1968 | ∅ | Soma: Divine Mushroom of Immortality | ∅ | ∅ | Gordon | ∅ | isbn:9780156838009 | ∅ | ∅ | Harcourt Brace Jovanovich
10. Wasson, R | 1978 | ∅ | The Road to Eleusis | ∅ | ∅ | Gordon, Albert Hofmann, and Carl A | ∅ | isbn:9780151778720 | ∅ | ∅ | P; Ruck; Harcourt Brace Jovanovich
11. McKenna, Terence | 1992 | ∅ | Food of the Gods | ∅ | ∅ | Bantam | ∅ | isbn:9781096950868 | ∅ | ∅ | ∅
12. Petri, G., et al | 2014 | "Homological Scaffolds of Brain Functional Networks" | Journal of the Royal Society Interface | ∅ | 101::20140873 | 11, no | ∅ | ∅ | ∅ | ∅ | ∅
13. Carhart-Harris, Robin L | 2014 | "The Entropic Brain: A Theory of Conscious States Informed by Neuroimaging Research with Psychedelic Drugs" | Frontiers in Human Neuroscience | ∅ | 8::20 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
14. Richards, William A. | 2015 | ∅ | Sacred Knowledge: Psychedelics and Religious Experiences | ∅ | ∅ | Columbia University Press | ∅ | ∅ | ∅ | ∅ | ∅
15. Sahagún, Bernardino de | 1950–1982 | ∅ | Florentine Codex: General History of the Things of New Spain | ∅ | ∅ | School of American Research | ∅ | isbn:9780874800081 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Research drawn from peer-reviewed clinical trials (NEJM, JAMA, Nature Medicine, PNAS), neuroimaging studies (Carhart-Harris 2012, 2014), and archaeological/ethnographic sources (Wasson, Sahagún). All sources verifiable. Last Updated: Mar 4, 2026